scholarly journals O uso do propranolol na terapêutica do hemangioma infantil

2021 ◽  
Vol 10 (8) ◽  
pp. e10010816968
Author(s):  
Vitoria Vilas Boas da Silva Bomfim ◽  
Maria Eduarda Lopes de Macedo Bezerra ◽  
Maria Clara Teles Cabanelas Macedo ◽  
Mikaele Montalvão Galliza Lima ◽  
Hanah Passos Carneiro ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Treatment

Objetivo: Avaliar o uso do propranolol como opção terapêutica para o hemangioma infantil, descrevendo as evidências encontradas na literatura, acerca das vantagens desta nova terapêutica quando comparada às terapias convencionais. Métodos: Trata-se de uma revisão integrativa de literatura, com artigos nas bases de dados Biblioteca Virtual de Saúde (BVS) e PubMed, nos idiomas português e inglês, utilizando os descritores “propranolol treatment”, “propranolol”, “infantile hemangioma” e “hemangioma of infancy”. Resultados: Foram encontrados na busca de literatura 1876 artigos, nos quais após a aplicação dos critérios de inclusão e exclusão e a revisão em pares ficaram 18 artigos a serem lidos na íntegra. Dos 18 artigos, foram incluídos 1380 pacientes que preencheram os critérios de inclusão. Um total de 56.5% eram do sexo feminino e compreendiam o intervalo de idade de 1 semana de vida a 9 anos de idade. Considerações Finais: O propranolol é considerado uma terapia alternativa para o tratamento do hemangioma infantil por apresentar uma eficácia elevada e menos efeitos adversos.

scholarly journals Propranolol Treatment of Vascular Anomalies Other Than Infantile Hemangioma

2017 ◽  
Vol 225 (4) ◽  
pp. S165
Author(s):  
Jeremy A. Goss ◽  
Dennis J. Konczyk ◽  
Mohammed H. Alomari ◽  
Reid A. Maclellan ◽  
Arin K. Greene
Keyword(s):  
Infantile Hemangioma ◽  
Vascular Anomalies ◽  
Propranolol Treatment

scholarly journals Propranolol treatment of infantile subglottic hemangioma: a report of two cases and a literature review

Folia Medica ◽  
2021 ◽  
Vol 63 (4) ◽  
pp. 601-607
Author(s):  
Kalina Ganeva ◽  
Petar Shivachev ◽  
Nikolay Sapundzhiev ◽  
Lora Nikiforova
Keyword(s):  
Literature Review ◽  
Inhaled Corticosteroids ◽  
Previous Treatment ◽  
Infantile Hemangioma ◽  
Benign Tumors ◽  
Close Monitoring ◽  
Upper Respiratory Tract ◽  
Life Threatening ◽  
Propranolol Treatment ◽  
The Subject

Infantile hemangioma is one of the most common benign tumors of infancy. The natural evolution includes rapid growth followed by gradual involution. Airway hemangiomas are not that common, but they can lead to dyspnoea, as well as to life-threatening complications. Two children aged 3 months were admitted to the Pediatric Department with difficulties in breathing and with biphasic stridor. They had previously been hospitalized because of the same symptoms and misdiagnosed as having an upper respiratory tract infection. The previous treatment included intravenous or inhaled corticosteroids, without any significant improvement. Laryngoscopy was performed for both of the children. There was a mass in the subglottic area with the appearance of a hemangioma causing significant airway stenosis. We started treatment with propranolol at a dose of 1 mg/kg/day twice daily. The dose was gradually increased up to 3 mg/kg/day, under close monitoring. In the first 7 to 10 days after initiation of treatment, we observed a significant improvement of the respiratory distress. The second laryngoscopy showed an almost complete involution of the mass in the subglottis.  The focus of this article will be primarily on the clinical presentation and the therapeutic response of subglottic hemangioma, along with a literature review on the subject.

Propranolol treatment of infantile hemangioma is not associated with psychological problems at 7 years of age

2017 ◽  
Vol 77 (1) ◽  
pp. 105-108 ◽  
Author(s):  
Andre Vadimovich Moyakine ◽  
Saskia Spillekom-van Koulil ◽  
Catharina Joanna Maria van der Vleuten
Keyword(s):  
Infantile Hemangioma ◽  
Psychological Problems ◽  
Propranolol Treatment

scholarly journals Infantil Hemangioma and Optimum Dose of Propranolol Treatment: A Retrospective Tertiary-Center Study

2021 ◽  
Author(s):  
Hatice Mine Cakmak ◽  
Omer Kartal
Keyword(s):  
Adverse Event ◽  
Optimal Dose ◽  
Infantile Hemangioma ◽  
Optimum Dose ◽  
Final Dose ◽  
Tertiary Center ◽  
Propranolol Group ◽  
Propranolol Treatment ◽  
Center Study

Abstract Background/Objectives: Propranolol is the mainstay treatment of infantile hemangioma, and the optimal dose is unclear. Few studies are comparing the efficacy of propranolol dose of 2 vs.3 mg/kg/day. We compared the efficacy between these two doses and propranolol groups with no treatment group. Methods: One hundred eight patients with infantile hemangioma (15 days-27 months of age) were examined. The patients with high-risk features and/or a score of >6 points are given propranolol with a final dose of 2 or 3 mg/kg/day according to tolerance for 6-12 months. The resolutions rates for propranolol vs. placebo and propranolol 2 mg/kg/day vs. 3 mg/kg/day are compared. Results: The demographic and clinical features of the groups ( the non-treatment, propranolol 2 mg/kg/day group, propranolol 3 mg/kg/day group) are similar. Propranolol is significantly efficent in infantil hemangioma treatment (p<0.001). The resolution rates are not statistically different between 2 mg/kg/day propranolol group vs 3 mg/kg/day propranolol group at the sixth (68,59 ± 28,95 vs 73,44 ± 32,54)(p=0,673) and twelfth month (p=0,673) (89,08 ± 46,58 vs 91,13 ± 37,46 respectively )of follow up. A milld (n=3)(4%) adverse event was reported with no need for cessation.Conclusions: Propranolol is a safe drug for treating infantile hemangioma with an ideal dose of 2 mg/kg/day rather than 3 mg/kg/day.

scholarly journals Propranolol treatment for infantile hemangioma: a case series of sixty-two patients

2016 ◽  
Vol 38 (2) ◽  
Author(s):  
Giovanna Stringari ◽  
Giulia Barbato ◽  
Matteo Zanzucchi ◽  
Maddalena Marchesi ◽  
Giuseppe Cerasoli ◽  
...  
Keyword(s):  
Case Series ◽  
Severe Hypoglycemia ◽  
Infantile Hemangioma ◽  
Treatment Length ◽  
Endoscopic Findings ◽  
Life Threatening ◽  
Propranolol Treatment ◽  
The Mean ◽  
The Impact ◽  
Oral Propranolol

Infantile hemangiomas (IH) complicated by ulceration, disfigurement, functional impairment or life-threatening conditions need early, safe and effective treatment. This study explores the impact of propranolol on complicated IH. We report our experience of 62 patients treated with oral propranolol for complicated IH. The effect of propranolol was assessed using a score on a visual analogue scale integrated with echo, magnetic resonance or endoscopic findings. The average age at the beginning of the treatment was seven months [standard deviation (SD)±8.9], with a median of four months (range 1-53 months). The average age at the end of the treatment was 15 months (SD±8.4), with a median of 13 months (range 7-59 months). The mean treatment length was eight months (SD±3.2). Oral propranolol was successful in 95.2% of the patients in reducing the volume, the intensity of color and the elevation of IH. Statistically significant improvement of IH volume was observed in the first two months of therapy (P≤0.001), and between the second month and the end of the treatment (P&lt;0.05). No significant bradycardia or hypotension occurred. Severe hypoglycemia occurred in one patient. Mild adverse effects were observed in seven patients. Our study demonstrates that propranolol administered orally at 2 to 3 mg/kg/day has a rapid therapeutic effect leading to remarkable shortening of the natural course of IH and it is safe in the majority of patients.

Recurrence of Infantile Hemangioma After Termination of Propranolol Treatment

2014 ◽  
Vol 72 (2) ◽  
pp. 173-175 ◽  
Author(s):  
Lei Chang ◽  
Gang Ma ◽  
Yunbo Jin ◽  
Xiaoxiao Ye ◽  
Yajing Qiu ◽  
...  
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Treatment

Hyperkalemia Complicating Propranolol Treatment of an Infantile Hemangioma

PEDIATRICS ◽  
2010 ◽  
Vol 126 (6) ◽  
pp. e1589-e1593 ◽  
Author(s):  
H. Pavlakovic ◽  
S. Kietz ◽  
P. Lauerer ◽  
M. Zutt ◽  
M. Lakomek
Keyword(s):  
Infantile Hemangioma ◽  
Propranolol Treatment
Sign in / Sign up

Export Citation Format

Share Document